The FDA has approved expanded labeling for Novo Nordisk’s Levemir (insulin detemir [rDNA origin] injection) to include children 2 to 5 years of age with type 1 diabetes. Insulin determir is now approved for glycemic control in patients from age 2 years through adulthood with type 1 diabetes and in adults with type 2 diabetes.